Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (August 2010)
22 slides from Zydus Lifesciences's investor presentation, August 2010
Slide 1: Cadila Healthcare Ltd. Investor Presentation
Cadila Healthcare Ltd. Investor Presentation August 2010 BSE : 532321 NSE : CADILAHC 1
Slide 2: Our Vision
Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020… 2
Slide 3: A Snapshot
A Snapshot One of the oldest and the 5th largest in the Indian formulations market worth over Rs. 425 bn (Source : ORG IMS MAT Jun-10) Operations in US, Europe, Japan, Latin America, Asia Pacific, Africa and Middle East regions International sales in generic markets contribute to ~39% of reven
Slide 4: Well integrated company and expanding Globally
Well integrated company and expanding Globally Revenue break up (%) by segment (FY 09-10) Indian finished International dosage finished dosage formulations formulations High end APIs + Consumer intermediates Wellness Revenue break up (%) by region (FY 09-10) Research and Manufacturing Development 4
Slide 5: State of the art facilities and infrastructure (1/2)
State of the art facilities and infrastructure (1/2) Formulations Finished Dosage Form, Finished Dosage Form, Finished Dosage Form, Moraiya (USFDA Approved) Sikkim Baddi Finished Dosage Form, Finished Dosage Form, Goa Agiolax (for Madaus), Goa Brazil Cytotoxic Injectables for Cytotoxic Injectable Ho
Slide 6: State of the art facilities and infrastructure (2/2)
State of the art facilities and infrastructure (2/2) APIs and Fine Chemicals R&D API, Ankleshwar API, Dabhasa Zydus Research Center, (USFDA Approved) (USFDA approved) Moraiya Fine Chemicals, Moraiya Biologics Active Substances, Pharmaceutical Technology (USFDA Approved) Changodar Center, Moraiya Pan
Slide 7: Financial highlights
Financial highlights # Net Profit and EPS exclude Exceptional Items. 7
Slide 8: 5th largest in Indian Pharma market
5th largest in Indian Pharma market with ~ Rs 15 bn sales Leading positions in key segments – CVS, GI, Female Healthcare and Respiratory (participated market segments) Therapeutic Area-wise Sales Break-up of Branded Formulations (FY 09-10) 16 brands amongst country’s top 300 brands Dermatology N
Slide 9: International formulations: two-fold focus
International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets (~29% of global sales) (~10% of global sales) 9 US - Zydus Pharmaceuticals USA Inc. 9 Brazil – 9 Europe • Branded - Quimica e Pharmaceutica Nikkho Do Brazil Ltda. • France - Zydus Fra
Slide 10: Among the top 20 generic companies in US
Among the top 20 and one of the fastest growing generic companies in US Started operations in 2005 and adopted a “Customer Centric Model” 32 products launched. 8 -10 products to be added every year 12 products enjoy >20% market share “Preferred Supplier” for many customers Focusing on deli
Slide 11: Market share in French market; product launches in Spain
Over 2.65 % market share in participated French market; 27 product launches in Spain Among top 10 in Euro 2.5 bn French generics market I Launched >160 presentations (~80 molecules) in France 8 Day-one launches among 14 launches in FY 09-10 Continuous focus on enrichment of customer relations
Slide 12: Strategies for Japan: World's 2nd largest pharma market
Strategies for Japan : World’s 2nd largest pharma market Generic market valued at >$ 3.5 bn, growing at ~12%, with very low generic penetration of ~6% in value terms, 19% in volume terms (Source : IGPA) Acquired Nippon Universal Pharma. Ltd. (NUP) with a marketing set-up and a small manufacturin
Slide 13: Strategies for $13bn Brazilian pharma market
Strategies for $ 13bn Brazilian pharma market Set up Zydus Healthcare Brazil Ltda (100% subsidiary) to enter generics market in 2005-06 Filed 59 dossiers so far for generic and branded products from India, of which 20 have been approved. Launched 14 generic products so far Acquired Nikkho in
Slide 14: Achievements in the fast growing emerging markets
Achievements in the fast growing emerging markets Operations in over 20 semi / non regulated emerging markets of Asia Pacific, Africa and Middle East regions Focusing on rapidly growing markets of South Africa, Taiwan and Philippines No.1 Indian company in Uganda and Sudan and amongst top 3 In
Slide 15: Strong brand equity in consumer wellness segment in India
Strong brand equity in highly potential consumer wellness segment in India Zydus Wellness Ltd. – spearheading operations in consumer wellness segment Strong presence in niche categories India’s largest selling sugar substitute with >80% market share (Source : AC Nielsen) Growing at CAGR of >
Slide 16: Unlocking value through win-win alliances
Unlocking value through win-win alliances Zydus Nycomed JV – most successful contract manufacturing JV in India State-of-the-art mfg. facility for Pantoprazole intermediates Expanded scope - more APIs to be sourced by Nycomed from this JV Zydus Hospira - JV for oncology injectables State-o
Slide 17: Ongoing Investment in Newer Portfolios
Ongoing Investment in Newer Portfolios Worth over $ 180 bn Long term Novel discovery products Mid term from Zydus NME pipeline Biogenerics : 40 bn Near term Transdermal : 10 bn Vaccine : 22 bn Pulmonary : 20 bn Topical : 16 bn Transdermal : 10 bn Current Business Injectables : 17 bn Oncology : 55 bn
Slide 18: A scientific talent pool of >950 and investing in research
A scientific talent pool of >950 and investing over 5.5% of the turnover on research Talent Pool of ~950 Scientists Zydus Research Centre (ZRC) Generics/ Located in Ahmedabad Developmental 400 scientists Focus on NME Research, Biologicals & NDDS Pharmaceutical Technology Centre NME & Drug (PTC)
Slide 19: Dedicated facility for NME research: Zydus Research Centre
Dedicated facility for NME research : Zydus Research Centre Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation Facility for target identification to pre- clinical research / early clinical development Signed a new drug discovery and development pact with Eli Lilly and Co., focused o
Slide 20: Biosimilars and Vaccines – The Next Big Opportunity
Biosimilars and Vaccines – The Next Big Opportunity Biosimilars : Strong pipeline: 15 biosimilars and 2 novel products Strong IP position either through own patent or non-infringing processes 120 experienced scientists dedicated to Biosimilars programme End to end product development and man
Slide 21: Key Financial Numbers – Q1 2010-11
Key Financial Numbers – Q1 2010-11 # Net Profit and EPS exclude Exceptional Items. * Excluding dossier licensing fees received from Abbott Labs. 21
Slide 22: Safe Harbour Statement
Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims a
Cadila Healthcare — Investor Presentation (August 2010) on 6ix